SANTA ROSA, Calif., Nov. 6, 2014 /PRNewswire/ -- Ruthigen, Inc., (NASDAQ: RTGN) today announced that the financial results for its fiscal second quarter 2015, ended September 30, 2014, will be released after the U.S. markets close on November 13, 2014. The earnings release will be followed by a conference call at 1:30 p.m. PDT (4:30 p.m. EDT) on November 13, 2014, to discuss fiscal second quarter 2015 results.
Individuals interested in participating in the conference call may do so by dialing 1-888-347-1332 for domestic callers or 1-412-902-4278 for international callers. Those interested in listening to the conference call live via the internet may do so at http://www.videonewswire.com/event.asp?id=101000. Please log on approximately 30 minutes prior to the presentation in order to complete the registration process.
A telephone replay will be available for seven days following the conclusion of the call by dialing 877-344-7529 for domestic callers, or 412-317-0088 for international callers, and entering conference code 10056012. A webcast replay will be available on the site at http://www.videonewswire.com/event.asp?id=101000 for one year following the call.
About Ruthigen
Ruthigen is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications. The company’s lead drug candidate, RUT58-60, is a broad-spectrum anti-infective that Ruthigen is developing for the prevention and treatment of infection in surgical and trauma procedures. The addressable market for RUT58-60 is approximately 30 million surgical and trauma procedures that are performed annually in the United States. The company’s clinical program targets an initial $700 million potential market in the prevention of infections associated with abdominal surgery, with the market for the prevention of infections associated with all types of surgery being estimated at $3 billion. Ruthigen plans to complete its Phase 1/2 clinical trial in Q1 2015 and, pending the successful completion of that trial, to conduct pivotal clinical trials. For more information, visit www.ruthigen.com.
SOURCE Ruthigen, Inc.
Help employers find you! Check out all the jobs and post your resume.
